In rodent models of AD, Singh and colleagues found that guanabenz treatment provided substantial protection against AD-specific behavioral and pathological markers, including alterations in acetylcholinesterase activity, tau phosphorylation, amyloid precursor protein processing, and memory retention [159]. The gene discussed is MAPT; the disease is Alzheimer disease.